Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of the rise of the chatbots: transforming genetics clinical delivery and research.

Personalized medicine·2026

Same author

Pharmacotherapy for alcohol misuse: Views of patients, providers, and leaders in an Alaska Native healthcare system.

Journal of substance use and addiction treatment·2026

Same author

STRIPE partners in precision medicine series: Patient perspective.

The pharmacogenomics journal·2026

Same author

Advancing the science of genomic learning healthcare systems.

Learning health systems·2025

Same author

Attitudes About Alcohol Misuse Among Alaska Native People in a Tribal Health Care System.

Journal of addiction medicine·2025

Same author

Artificial intelligence, medications, pharmacogenomics, and ethics.

Pharmacogenomics·2024

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Pharmacogenetic testing: not as simple as it seems.

Susanne B Haga¹, Wylie Burke

¹Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina27708, USA. susanne.haga@duke.edu

Genetics in Medicine : Official Journal of the American College of Medical Genetics

|May 23, 2008

Summary

Pharmacogenetic testing offers personalized medicine but raises ethical concerns. A new classification framework addresses policy issues for safe and effective clinical integration of pharmacogenetic tests.

More Related Videos

Pyrosequencing: A Simple Method for Accurate Genotyping

Pyrosequencing: A Simple Method for Accurate Genotyping

Published on: January 8, 2008

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: Jul 5, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Pyrosequencing: A Simple Method for Accurate Genotyping

Pyrosequencing: A Simple Method for Accurate Genotyping

Published on: January 8, 2008

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

Pharmacogenetics
Clinical Pharmacology
Bioethics

Background:

Pharmacogenetics aims to optimize drug selection and dosage for individual patients.
Despite its potential, pharmacogenetic testing presents ethical challenges and clinical uncertainties.
Existing approaches may overlook crucial policy considerations for widespread adoption.

Purpose of the Study:

To propose a classification system for pharmacogenetic tests.
To identify and prioritize policy issues essential for appropriate pharmacogenetic test delivery.
To analyze benefits and risks related to ancillary information, testing timing, and data management.

Main Methods:

Development of a pharmacogenetic test classification framework.
Application of the framework to evaluate ethical and clinical considerations.
Analysis of implications for informed consent, genetic counseling, and healthcare professionals' roles.

Main Results:

The proposed classification highlights key policy areas requiring attention.
Considerations include managing ancillary genetic information, optimal timing of tests, and secure data storage.
These factors significantly impact informed consent, genetic counseling, and professional responsibilities.

Conclusions:

Pharmacogenetic testing, while promising, necessitates careful ethical and policy navigation.
A structured approach is crucial for addressing risks and uncertainties in clinical implementation.
Policy development must guide the responsible integration of pharmacogenetics into healthcare.